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Abstract
Amyloid aggregates are highly ordered fibrillar assemblies of polypeptides involved in a number
of neurodegenerative diseases. Very little is known on the pathways of self-assembly of peptides into
the final amyloid fibrils, which is due in part to the difficulty of triggering the aggregation process in
a controlled manner. Here we present the design and validation of a cross-linked hexapeptide that
reversibly aggregates and dissociates under ultraviolet light irradiation control. First molecular
dynamics simulations were carried out to identify, among hundreds of possible sequences, those
with the highest propensity to form ordered (β-sheet) oligomers in the trans state of the azobenzene
cross-linker, and at the same time with the highest solubility in the cis state. In the simulations,
the peptides were observed to spontaneously form ordered oligomers with cross-β contacts when
the cross-linker was in the trans state, whereas in the cis state they self-assemble into amorphous
aggregates. For the most promising sequence emerging from the simulations (Ac-Cys-His-Gly-Gln-
Cys-Lys-NH2 cross-linked at the two cysteine residues), the photo-isomerization of the azobenzene
group was shown to induce reversible aggregation by time-resolved light scattering and fluorescence
measurements. The amyloid-like fibrillar topology was confirmed by electron microscopy. Potential
applications of minimally-designed peptides with photoswitchable amyloidogenic propensity are
briefly discussed.
Keywords: Amyloid, Fibril
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I. INTRODUCTION
Amyloidogenesis has been implicated as an important factor in a number of neurolog-
ical and systemic diseases1. Amyloid fibrils, the products of amyloidogenesis, consist of
ordered self-assemblies of polypeptides stabilized by inter-molecular cross-β contacts (β-
interactions). They form with a characteristic fibrillar morphology which often collect cel-
lularly into larger structures such as plaques in Alzheimer’s and Lewy bodies in Parkinson’s
diseases2,3. The cytotoxicity of amyloid aggregation has been linked to the presence of in-
termediates. For example, studies have shown that it may be the prefibrillar aggregates
that cause cell death in Alzheimer’s disease4 and not the large mature fibrils found in the
same tissues. In fact, the amyloid fibril formation is a multi-step process that involves a
nucleation phase, where initial oligomers assemble, and an elongation phase, during which
protofibrillar intermediates are formed5–8 and grow to mature fibrils by monomer docking
and peptide structural rearrangement9,10.
To unravel the nature of amyloid aggregation, it is crucial to understand the pathways and
the structural details of the earliest steps in self-assembly. Computer simulation of polypep-
tide self-aggregation has shed some light on the process of amyloidogenesis. Atomistic models
have been employed to study the conformational space of amyloidogenic polypeptides in the
monomeric state11,12, the very initial steps of amyloid formation13–19, and the structural
stability of fibril models20–24. In particular, simulation studies of early oligomerization, in-
volving a few peptides or polypeptide fragments, have provided important insight into the
detailed molecular mechanism and sequence determinants in amyloid formation13,14,16,25–29,
aggregation inhibition30–33 and, nucleation19,34,35.
Experimentally, it is possible to measure early events of aggregation in vitro using
stopped-flow or other mixing methods36, however amyloid aggregation can be unpredictable
and difficult to work with. Often, the onset of aggregation starts immediately following
the initial preparation of a peptide solution, well before any measurement is possible. For
other solutions, it can take between minutes and days for aggregation to start and can vary
from preparation to preparation even with identical peptide sequences or different portions
of the same sample37. Many groups have found solutions to these problems. For example,
by modifying amyloid peptide sequences through the introduction of a “host-guest switch”,
aggregation can be initiated reliably upon the addition of an enzyme or change in pH38.
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These modifications facilitate time resolved experiments studying aggregation growth, how-
ever many of the standard mixing experiments such as stopped-flow are still limited by the
time resolution of the detector or by the dead-time of the instruments. One method that
resolves these limitations is to use photo-control as a trigger for aggregation, for example
by modifying the amyloid peptide with a photo-cleavable protective group that inhibits ag-
gregation39. Others have demonstrated that the presence of a photosurfactant can inhibit
amyloid aggregation depending on illumination40,41.
The photo-control method used in this study was the incorporation of a photoswitchable
molecule into a peptide, such that one photoisomer is more prone to amyloid fibril formation
than the other. Among the various photoswitchable molecules, azobenzenes are extensively
utilized in bottom-up design of biomaterials because of their efficient and reversible photoiso-
merization that leads to large changes in molecular geometry. Some studies have employed
azobenzene-modified peptides as reversible aggregation units. In one study a tripeptide
fused with azobenzene forms fibrillar aggregates via β-sheet interactions42. In another work,
two cyclic octapeptides are bridged by azobenzene whose isomerization state controls the
conversion between intra- and intermolecularly assembled cylindrical structures43. It has
been found that the aggregation propensity of a β-hairpin peptide with an azobenzene in-
corporated in the backbone changes depending on the conformation of the photoswitch44.
Recently these studies have been extended to show that such a system can form amyloid-like
structures when the azobenzene is in an extended conformation45.
The present work is motivated by the following question: what is the minimal possible
design of a photoswitchable peptide whose amyloid association can be triggered and reversed
in a controllable manner? We attempt to answer this question by employing a simulation-
based approach, where we design an azobenzene cross-linked peptide whose equilibrium
between the β-aggregation prone and soluble conformations is photo-controllable. Given
the minimal length of the peptide, the design process was based on an almost exhaustive
screening of peptide mutations, simulated and selected based on their self-aggregation be-
havior. Experimental assays performed on the selected sequence show that the synthesized
photo-controllable peptide does form amyloid-like fibrils when the photoswitch is in an ex-
tended conformation and that the aggregates disassociate upon illumination such that the
cross-linker is switched into a compact conformation. Moreover, this process of aggregation
and disassociation can be repeated multiple times on the same sample.
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II. MATERIAL AND METHODS
Simulations protocols. All simulations were performed with the program CHARMM46.
For the implicit solvent simulations, the peptides were modeled using the united hydrogen
force field PARAM19 that explicitly accounts for heavy atoms and polar hydrogens bound
to nitrogens or oxygens. The default truncation scheme for non-bonding interactions was
set to 7.5 A˚. Protonation states of titratable residues were set according to those found at
pH 7.0. During the first sequence selection, an efficient mean field approximation based on
the Solvent Accessible Surface Area (SASA) was used to describe the main effects of the
aqueous solvent47. Formal charges were neutralized and electrostatic screening was emulated
by a distance dependent dielectric constant. For the second sequence selection a more
accurate Generalized Born implicit solvent (FACTS) was used with non-neutralized formal
charges48. Non-polar solvation was approximated by a term proportional to surface area with
a multiplicative surface tension-like parameter of 7.5 kcal/(mol·A˚−2). SHAKE was used to
fix the covalent bonds involving polar hydrogens49. All implicit solvent simulations were
carried out with periodic boundary conditions at a fixed peptide concentration of 5.3 mM
(corresponding to a box size of 98 A˚ for the trimer and 135 A˚ for the octamer simulations),
using Langevin integration of motion equations with a time step of 2 fs, low friction constant
(0.1 ps−1), and at constant temperature of 330 K and 310 K for the SASA and FACTS
simulations, respectively. Simulations were performed with either three or eight replicas
of the same peptide sequence with all linkers either in the trans or cis conformation. The
peptides were initially monodispersed and the configurations were individually equilibrated,
to avoid biasing effects on the aggregation process. The aggregation simulations are sub
microsecond equilibrium simulations of the spontaneous oligomerization. A 1.0-µs run with
implicit solvent takes less than one week on a single AMD Opteron 252 CPU at 2.6 GHz.
The explicit water simulations were carried out using the CHARMM PARAM22 all-atom
protein force field and the TIP3P model of water. An octahedral box of 50 A˚ per side was
used; it contained 2613 water molecules in addition to 12 chloride and 4 sodium ions. Periodic
boundary conditions were applied, together with the particle-mesh Ewald, which was used
for the long-range electrostatic interactions. The van der Waals interactions were truncated
at a cutoff of 12 A˚ and a switch function was applied starting at 10 A˚. The trajectories were
produced at 300 K, kept constant using Nose-Hoover thermostat, and pressure of 1 atm
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using a Langevin piston, with an integration time step of 2 fs. An equilibration of 0.5 ns
was performed before the production runs which consisted of 200 ns (two runs) and 50 ns.
Simulations analysis. Since the simulations were run under different conditions, (i.e.,
cis and trans configurations, different implicit solvents) there was not a single observable
that was optimally sensitive to rank the sequences for all the selection steps. Therefore,
to evaluate the aggregation propensity of the simulated peptides sequences, a number of
observables were introduced, as discussed below, and the sequence ranks were made by
choosing the observable with the highest sensitivity upon sequence change. For instance,
the first sequence selection, based on SASA implicit solvent simulations, was performed by
ranking the sequences using the order parameter, whereas in the second selection we used
the number of backbone hydrogen bonds and radius of gyration for the trans and cis systems,
respectively.
Order Parameters. Nematic and polar order parameters P2 and P1, originally intro-
duced to describe the molecular arrangement of liquid crystals50,51, are useful quantities to
monitor the structural transition within peptide oligomers16,52. The order parameter P2
measures the amount of β-structure of the system by determining the fraction of aligned
molecular components, here represented by N molecular unit vectors zˆi that join the Cα
atom of residue i to the Cα atom of residue i + 2. P2 is defined as:
P2 =
1
N
N∑
i=1
3
2
(
zˆi · dˆ
)2
− 1
2
,
where the unit vector dˆ defines the predominant direction of all molecular unit vectors,
and is obtained as the eigenvector of the ordering matrix that corresponds to the largest
positive eigenvalue. The values of P2 range from 0 to 1, which respectively correspond to
complete disorder and complete order. Complete order is achieved when all the unit vectors
are parallel or antiparallel, while the disorder is obtained when none of unit vectors are
parallel to any of the others. Since the P2 parameter distribution of a trimer that reversibly
oligomerizes into ordered structures is typically bivariate, with one peak close to 1 and a
broad peak at 0.5, to assess the order of a full equilibrium trajectory we found it convenient
to define the order-disorder ratio rP2, which is the frequency that the order parameter is
lower than a cutoff value P ∗2 =0.65 (disorder) divided by the frequency that it is higher than
P ∗2 (order). The cutoff value was determined to maximize the sensitivity of rP2 (See Ref. 30).
6
The polar order parameter P1 accounts for the number of molecular vectors zˆi pointing
in the same direction, and discriminates between parallel and antiparallel/mixed ordered
aggregates, for which P1 has a value of 1 and 0, respectively. It is defined as:
P1 =
1
N
N∑
i=1
zˆi · dˆ.
Hydrogen bonds. The number of intermolecular and intramolecular backbone hydrogen
bonds was used to quantify the propensity of the peptides to form cross-β interactions. The
criteria for hydrogen bonds are that the H-O distance is shorter than 2.5 A˚ and a NH-O
angle larger than 130 degrees.
Radius of gyration. The radius of gyration Rg was used to quantify the compactness
of the oligomers. It is evaluated as the square root of the mean squared deviation of the
C-α atom positions from the geometric center of the oligomer R2g =
1
N
∑N
i=1(ri− rmean)2. A
high value ( > 22 A˚) corresponds to a dissociated trimer, while a low value (< 10 A˚) is a
compact trimer. rRg is the ratio of the number of trajectory frames where the peptides Rg
higher and lower than the threshold value 14 A˚, empirically set according to Rg frequency
distribution evaluated along the simulations (see Fig. S3).
Parametrization of the Cross-Linker. The atom types that comprised the cross-
linker were derived from the PARAM19 and PARAM22 force fields (See Ref. 53 for more
details). The cis and trans isomerization states of the C-N=N-C bond are enforced by a
dihedral potential with a single minimum at 0 and 180 degrees respectively.
Construction of the cross-linked peptide model. Initial models of the cross-linked
peptide with the azobenzene in the trans or cis configuration were built from the extended
configuration of the peptide. The two cysteine Sγ atoms were attached to each half of
the cross-linker, which was split at the N=N bond. Initially the modified sidechains were
arbitrarily oriented, violating the N=N bond length. A dihedral potential with a minimum
at the angle corresponding to the trans (or cis) configuration was then applied at the C-
N=N-C bond. The model was then minimized to get rid of clashes and violated bonds,
restoring the integrity of the cross-linker.
Peptide synthesis and cross-linking. The azobenzene cross-linker was synthesized
and fused to the peptide according to the procedure detailed in Ref. 54 . The His.Gln pep-
tide, with sequence Ac-Cys-His-Gly-Gln-Cys-Lys-NH2, was purchased from GL Biochem
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Ltd. (Shanghai). The product was then further purified by high pressure liquid chromatog-
raphy. Any residual TFA was removed using an ion exchange column (Varian BOND ELUT
SAX, Agilent Life Sciences). The final product was then resuspended in buffer and filtered
through a 0.22 µm filter before use in aggregation experiments.
Fibril formation. Stock solutions of cross-linked peptides were prepared in 10 mM
phosphate buffer at various pH values, a final concentration of about 0.3 mM, and volume
of 3 ml in a quartz 10 mm path length cuvette. The solutions were stirred continuously
by a small magnetic stir bar, which was periodically lifted once per minute for about 2-3
seconds to inhibit aggregation on the surfaces of the cuvette. Aggregation became visible
(the solution would appear cloudy) within hours to days after the peptides initial suspension.
Scattering studies. Scattering measurements were taken using a home built apparatus
described briefly as follows: a red LED provided the source of the scattered light and a
phototransistor, mounted at 90 degrees from the source, was used to measure the scattered
light. The light source was modulated at about 3 kHz and any scattered light produced
by particles such as fibrils were collected on the detector. The signal was then amplified
and run through a high-pass filter, rectified and read by an AD converter. A micropro-
cessor controlled both the apparatus, and recorded measurements. The entire apparatus
was compact enough that it could be placed on top of a magnetic stir plate such that the
solution was stirred continuously and any aggregates could not settle to the bottom of the
cuvette. The apparatus also included a small, mechanically controlled magnet that could
be lowered adjacent to the cuvette such that the oscillating stir bar was raised to the upper
half of the solution and then dropped and was controlled automatically by the apparatus
microprocessor. This motion took about 2 or 3 seconds, was set to occur periodically every
minute and was important to inhibit the production of aggregation on the surfaces of the
cuvette. A 365 nm wavelength LED was used to switch the conformation of the azobenzene
photo-switch from trans to cis. Since the UV light source was not modulated, it did not add
to the scattering signal.
TEM imaging. Peptide solutions were prepared in 10 mM sodium phosphate buffer
at varying pH with a final concentration of about 0.3 mM and allowed to aggregate for at
least 24 hours. Samples were taken from the aggregated peptide solutions (6 µl) and applied
to previously glow discharged, carbon-coated 300 mesh copper grids, for one minute. The
excess solution was immediately blotted dry with filter paper, and the grids were then
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stained for two minutes with 2% (w/v) uranyl acetate in water. Microscopy was performed
with a Philips CM100 transmission electron microscope operating at an accelerating voltage
of 80kV. High-resolution TEM images were captured with a fitted 4k × 3k pixel 12-bit
Gatan digital camera. TEM images comparing trans and cis conformations were taken from
the same solutions previously used in scattering measurements to observe photo-initiated
disassociation and re-aggregation.
Fluorescence measurements. Solutions were prepared according to Nilsson et al.
(Ref. 55), and are briefly described here: A stock solution of PTAA-Li was prepared at a
concentration of 1 mg/ml in deionized water. 10 µl of this solution was mixed with 15 µl of
the peptide solution and diluted to a final volume of 2 ml in 20 mM pH 7 phosphate buffer.
The solution was incubated at room temperature for 5 minutes. Emission and excitation
spectra were recorded with a HORIBA Jobin Yvon, Fluorolog 3 fluorometer.
III. SIMULATION RESULTS
Initial sequence design. One basic premise behind our photoswitchable peptide se-
quence design is that the β-aggregation prone conformation corresponds to a fully extended
configuration of the peptide. In this conformation we assume that the backbone amide hy-
drogens and carbonyls are solvent exposed and susceptible to involvement in intermolecular
hydrogen bonds. This premise, along with the characteristics of the azobenzene-derived
cross-linker, described by the Woolley group54, introduce much of the primary restraints for
a minimal amyloid peptide design. The cross-linker is anchored to the peptide at both ends
to cysteine residues by thiol chemistry, and has two photoisomers: a compact cis state, and
an extended thermally-stable lower-energy trans state. Therefore, the end-to-end distance
of the cross-linker in the trans state dictates the size of the peptide, which we found to be
about 5 residues, named here X1 − X5 counting from the N-terminus. In order to anchor
the cross-linker, X1 and X5 must be cysteine residues, leaving X2X3X4 free to be varied
systematically. Isomerization can be driven in both directions: from trans to cis by illumi-
nating with 365 nm light, or in the other direction by 430 nm light. In our design, the trans
conformation of the cross-linker induces an aggregation prone conformation of the peptide.
Preliminary simulations and computer modeling (not shown) revealed that the cross-linked
pentapeptide tolerates isomerization of the photoswitch by altering the structure of the
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peptide backbone. When the linker is in the cis state, the peptide backbone rearranges
into a collapsed configuration, which is an ideal β-aggregation protected conformation since
the backbone amide hydrogens and carbonyls are sequestered by intramolecular hydrogen
bonds, reducing their ability to form ordered cross-β interactions. The peptide is capped by
uncharged acetyl and N-methylamide groups at the N- and C-terminus, respectively.
Selection of the sequences. We chose a simulation-based strategy to design a minimal-
length sequence for the cross-linked peptide, which we then validated by further simulations
and experiments. The design had two fundamental requirements: first, the sequence must
have the highest β-aggregation propensity when the cross-linker is in the trans conformation,
and second, it must have the highest solubility in the cis conformation. The combination
of these two opposing requirements determined the peptide sequence with the most distinct
transition between the amyloid-prone and the soluble state. We organized the sequence
design process (Fig. 1) by progressively increasing the complexity of the system from implicit
solvent simulations of trimeric systems to the final experimental validation of the selected
sequence (see Tab. 1). We estimated the β-aggregation propensity of a given sequence
using the order parameters P1, P2 and rP2 (see Material and Methods), which account for
the amount of parallel structure and molecular order in the oligomers, and the number of
intramolecular backbone hydrogen bonds over the produced simulation trajectories.
Effect of alanine and glycine at position X3. Computer modeling of the trans state
cross-linked peptide, with X2 and X4 set to alanines and X3 spanning a number of different
residues (not shown), revealed that position X3 must be occupied by a small residue, either
glycine or alanine. In fact, when the peptide backbone is in a β-conformation, the side
chain at position X3 points in the same direction as the X1 and X5 cysteine sidechains with
respect to the plane defined by the β-sheet, and clashes against the linker. Implicit solvent
aggregation simulations of trimeric CAGAC and CAAAC sequences with the cross-linker
in the trans state revealed that an alanine side chain at position X3 is sufficiently large to
hinder ordered β-aggregation, as revealed by the decreased nematic order parameter ratio
rP2, the decreased number of intermolecular hydrogen bonds, and the increased radius of
gyration (see Tab. 2). We therefore decided to proceed by setting position X3 to glycine on
all subsequent sequence screenings.
Positions X2 and X4, first selection round. Using implicit solvent simulations, we
filtered out all sequences that were not able to oligomerize into ordered β-structures with
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the cross-linker in the trans configuration. At positions X2 and X4 we considered all possible
residue combinations, excluding: those with charged sidechains (to avoid electrostatic repul-
sion); proline and glycine (which are β-breaker residues); and cysteine (to avoid incorrect
cross-linking to the peptide). This left 169 possible sequences, which we have labeled with
the compact symbol X2.X4 (shorthand for the full sequence Cys-X2-Gly-X4-Cys), each of
which were modeled in the trans configuration and used in trimeric aggregation simulations
using SASA implicit solvent run for about 0.5 µs (see Methods).
During the simulations the peptides sampled different oligomerization states, including
monomers, dimers, and trimers, with different β-interaction arrangements (parallel, antipar-
allel, and mixed cross-β interactions). We ranked the equilibrium trajectories according to
the average order parameter ratio rP2 (Tab. S1). Note that the number of intermolecular
backbone hydrogen bonds correlates with rP2 and that no intramolecular hydrogen bonds
were formed due to the extended conformation of the peptides.
Positions X2 and X4, second selection round. The 26 best ranked sequences of the
first selection round were used to start trimer aggregation simulations using the FACTS48
implicit solvent model (see Methods) which is more accurate but less efficient than SASA.
Taking into account the limitations of F-moc synthesis for any peptides that might be synthe-
sized for experiments, the sequences were modified by appending a lysine at the C-terminus
of the peptide in order to increase the yield and solubility. All 26 sequences were simu-
lated with the cross-linker in the cis and trans conformations, for a total of 52 simulations.
Compared to SASA, FACTS implicit solvent is closer to an aqueous environment because
of higher effective dielectric screening. This resulted in less compact and more disordered
oligomers, and the rP2 parameter became too noisy to measure appreciable differences be-
tween the sequences. For this reason, the trans simulations were instead ranked according to
increasing average number of intermolecular hydrogen bonds, which in this case is more suit-
able and sensitive to structural changes (Tabs. 3 and S2). The cis simulations were ranked
according to increasing values of the radius of gyration ratio rRg, in order to favor sequences
that are more soluble (Tabs. 3 and S3). The total score used to rank each sequence was
determined by summing the individual ranks of the cis and the trans simulations. Hence,
lowest scored (i.e., highly ranked) sequences corresponded to the variants with the most
desired properties (i.e., being β-aggregation prone in the trans configuration and soluble in
the cis configuration).
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Octamer simulations. We selected the four highest ranking sequences, X2.X4=His.Ala,
His.Gln, Phe.Ala, His.Met (Tab. 3), for octamer aggregation simulations, with all the cross-
linkers in either trans or cis configurations. Visual inspection of the trajectories revealed that
in the trans configuration the initially monodispersed peptides spontaneously nucleated into
β-sheet containing aggregates with transiently different registers and arrangements (Figs. 2
and 3), as reflected by the fluctuations in the number of intermolecular backbone hydrogen-
bonds (see Figs. S2). Structural analysis of the four aggregation simulations (Fig. 2f)
showed that among all sequences His.Gln had the highest amount of intermolecular backbone
hydrogen bonds, as well as the highest molecular order and parallel aggregation content, as
showed by the P2 and P1 order parameters. Although having different stabilities, the four
sequences mainly nucleated into two β-sheet ordered structures, with the azobenzene acting
as a hydrophobic surface buried in the interior.
The nucleation of the His.Gln ordered aggregate and the formation of the cross-β inter-
actions occurred in a disordered micellar oligomer (Fig. 3). After about eight nanoseconds,
the first dimer associated through intermolecular contacts between the azobenzene moieties.
In the subsequent 100 ns the other six monomers attached to the dimer by establishing
hydrophobic contacts through the cross-linkers. At this stage the oligomer displayed the
properties of a disordered micelle, with the hydrophobic azobenzene moieties buried inside
and the hydrophilic histidine, glutamine and lysine sidechains pointing outward. On av-
erage, the micellar octamer had a total of seven backbone intermolecular hydrogen bonds
(less than one per monomer), and transiently formed a β-sheet structure. In the following
50 ns, ordered cross-β interactions propagated quickly, as shown by the increasing number
of intermolecular hydrogen bonds, to an average of 17.
Visual inspection of the nucleation process revealed that the formation of the amyloid
oligomer is a two-step structural rearrangement. When the first four-stranded β-sheet is
formed, the oligomer is half-ordered and half-disordered. The two halves are in contact
through the eight azobenzenes, where the four belonging to peptides integral to the β-sheet
are stably arranged in a stack, and the remaining azobenzenes are unspecifically attached.
The ordered tetramer part induces β-sheet formation on the disordered part within about
30 ns. The resulting structure, two parallel β-sheets assembled through azobenzene interac-
tions, is very stable and does not change throughout the following 900 ns.
When the cross-linker is in the cis conformation, the peptides assemble into disordered
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aggregates with few intermolecular and intramolecular hydrogen bonds (Fig. 2e, 3b and S1)
and with low molecular order (P2 ∼0.3). A comparison of the radius of gyration frequency
distributions between the cis and trans His.Gln aggregates shows that in the former state,
due to the weaker interactions between the peptides, the oligomer is less compact (Fig.
3c). In the cis state of the cross-linker, the average radius of gyration Rg is independent of
the simulated sequence (Fig. 2f), and the aggregates appear as spherical micelles with the
azobenzene buried inside (see Fig. 2e), similar to the on-pathway oligomers initially formed
during trans-peptides aggregation.
Explicit water simulations. The results of the octamer aggregation simulations
above showed that the His.Gln peptide sequence is more prone to form stable and ordered
oligomers. We decided to proceed with this sequence and validate the design with further
computer simulations and experimental assays.
To assess the structural stability of the ordered aggregates formed in an implicit solvent,
we started three explicit solvent simulations (Fig. 4a) using the octamer conformation
with the highest number of backbone hydrogen bonds explored during the previous trans
aggregation simulations. In two of the trajectories, the parallel arrangement of the peptides
and the cross-β interactions were conserved over the entire duration of the simulation. The
Cα-RMSD value, with respect to the starting structure, is below 3 A˚ and the oligomer
has an average of about 17 intermolecular backbone hydrogen bonds — in agreement with
the implicit solvent average value (see Fig. 4a). Although in explicit solvent the oligomer
did not substantially change the double β-sheet morphology formed in implicit solvent, it
transiently explored two distinct arrangements of the azobenzene packing, showing that
the ordered oligomer dynamically exchanges between alternate arrangements of the two
β-sheets (Figs. 4b and 4c). In one arrangement each azobenzene fully interacts with a
single corresponding facing linker (Fig. 4b), whereas in the other arrangement it interacts
with linkers belonging to two facing neighboring peptides (Fig. 4c). Furthermore, visual
inspection of the simulations revealed that the amide groups of the cross-linker are transiently
involved in inter- and intra-β-sheet hydrogen bonds that contribute to the stability of the
ordered oligomer (Fig. 4e and 4f).
In the remaining simulation (simulation 2 in Fig. 4a), after about 1 ns two monomers
at one edge of the oligomer separated from the β-sheets by breaking all backbone hydrogen
bonds. The two monomers remained attached to the oligomer through non-polar azobenzene
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interactions, and after 40 ns one of the monomers dissociated, as revealed by the increase of
Cα-RMSD. Besides the two disordered peptides, the remaining ordered hexamer, comprised
of a double three-stranded β-sheet, basically conserved the same configuration as that in the
original oligomer until the simulation was halted after about 50 ns (see orange time series
in 4a).
IV. EXPERIMENTAL RESULTS
Aggregation Experiments. To test the aggregation properties of the photoswitchable
peptide, we synthesized and cross-linked the His.Gln sequence. We measured the aggrega-
tion kinetics, assessed the photo-induced reversibility of the association and determined the
structural nature of the aggregation using three different series of experiments: static light
scattering, fluorescence, and transmission electron microscopy (TEM). Static light scatter-
ing measurements were used to monitor the aggregation level of the peptides in the sample
without giving information on morphology of the aggregation itself. To determine the pres-
ence of amyloid structure and the fibrillar nature of the aggregated samples, we performed
fluorescence binding assays using a new class of dyes and produced TEM images of the
aggregants.
Scattering Experiments. We performed time-resolved light scattering experiments,
measured the level of aggregation on the His.Gln peptide under the presence and absence
of UV light. The time-series of the scattered light intensity clearly confirmed the reversible
association properties of the cross-linked peptide (Fig. 5). In fact, the samples aggregated in
absence of UV illumination, and disassociated when exposed to UV light; much as predicted
for the trans and cis conformation of the cross-linker. In a typical scattering experiment,
a freshly prepared solution was placed in the light scattering instrument and monitored
immediately with measurements taken every minute. The sample would begin to aggregate
and light scattering was allowed to reach a steady maximum. The solution would then be
illuminated under 365 nm UV light to induce disassociation until the scattering intensity
reached a stable minimum. This sequence could then be repeated any number of times.
A full aggregation trajectory, comprising the initial aggregation phase immediately after
the peptide solution was produced, and a series of UV-illuminations followed by UV-absent
time-intervals, were typically run reproducibly over days to weeks.
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Aggregation was found to have a strong pH dependence, with no sample prepared at a pH
less than 5 showing aggregation even after more than two weeks of observation. Moreover,
of the peptide solutions that did show aggregation, only those with pH 10 and lower showed
signs of photo-induced disassociation with the largest change in scattering at pH 7. Inter-
estingly, it was possible to observe association and disassociation for the pH 7 solutions by
eye, in that the initial aggregated solution appeared cloudy and became clearer and darker,
resembling the color of free azobenzene in solution following illumination with UV light (Fig.
S4).
Upon initial suspension, aggregation showed a lag phase ranging from hours to days before
an increase in scattering intensity could be detected. The aggregation process eventually
reached equilibrium, indicated by a sustained maximum scattering. This lag phase is similar
to that found in the non-photo-triggered studies mentioned in the introduction, and in the
same way the lag time could vary from batch to batch. Light scattering disassociation curves,
normalized and aligned such that time zero was when the UV light was first turned on, shown
in Fig. 5b, lie almost directly on top of each other, demonstrating that the disassociation
kinetics are highly repeatable. Reaggregation curves were also collected in the same manner,
normalized and aligned such that time zero was when the UV light was turned off, shown in
Fig. 5c. The reaggregation kinetics show a lag phase, much like those of other aggregation
experiments, with the delayed onset of measurable aggregation ranging from about 35 to 100
minutes after halting UV illumination, hence more predictable and reproducible than the
initial aggregation. Also, the scattering baseline for the lag-phase of the initial aggregation
is lower than the corresponding baselines for all of the photocontrolled disassociation. This
could be explained by the emergence of micron-scale clumps of aggregates, large enough that
the UV light source is not of sufficient intensity to convert 100% of the peptide photoswitches
to the cis conformation and to disassociate the entire aggregate. Therefore, in the initially
monodispersed sample there were no scattering oligomers, whereas at the end of each light-
induced disassociation, aggregates were possibly present due to residual trans photoswitches,
as evident from TEM micrographs (see below and Fig. 7b). A small residual population of
aggregation may also explain the smaller range of lag-times in the reaggregation kinetics in
comparison with the initial aggregation. Photo-induced disassociation and re-aggregation
could typically be cycled multiple times over the course of weeks as long as the sample was
kept sealed and stirred constantly.
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Fluorescence. A typical test for assessing the presence amyloid aggregates is by intro-
ducing Thioflavin T (ThT)56, which changes in fluorescence upon binding with amyloid or
amyloid-like fibrils. Specifically, an increase in emission intensity and a redshift of about
100 nm for the emission maximum is typically observed. Unfortunately, the emission and
absorption spectra of ThT largely overlap with the absorbance spectra of the azobenzene de-
rived photo-linker, due to the structural similarity of the cross-linker and the ThT molecule.
For similar reasons, absorbance measurements on Congo red (another frequently used amy-
loid indicator) were also not attempted. Instead, we chose a new class of fluorescent dyes:
luminescent conjugated polyelectrolyte probes (LCPs), which were specifically developed as
markers for amyloid fibrils55,57. These dyes bind non-covalently with fibrils and have spectra
that do not overlap with that of the photo-linker. The LCP used in these experiments, poly-
thiophene acetic acid (PTAA), has a fluorescence excitation maximum at about 400 nm and
can still be excited between 300 and 500 nm. When the LCP is in the presence of amyloid-
like fibrils, the fluorescence intensity increases significantly, doubling in the case of PTAA,
and is slightly redshifted. Often the excitation maximum is also redshifted. When PTAA
was tested with the His.Gln peptide solution, the change in fluorescence showed definitive
signs of amyloid fibril formation (Fig. 6). This was even more apparent when comparing
the fluorescence emission spectra between the peptide solution before and after UV light
exposure. Before exposure, when the level of peptide aggregation was high, the fluorescence
intensity was greater than double that following photo-induced disassociation. Apart from
the absence of blue shift in the excitation spectrum, the spectra appear consistent with those
measured for PTAA in the presence and absence of Aβ peptide aggregation, as investigated
previously55.
Transmission Electron Microscopy. To determine the morphology of the peptide
assemblies, we produced a number of TEM micrographs of the samples taken after the initial
aggregation, as well as following photo-induced disassociation and re-aggregation. Initially
aggregated His.Gln peptides clearly show the presence of fibrils with an average length of
400 nm, and 6-8 nm thickness (Fig. 7a). The peptide solution was then exposed to UV light
for 2 hours and the scattering monitored. Samples were taken once the scattering intensity
reached a stable minimum value. Subsequently, in absence of UV light, aggregation was
allowed to proceed and samples were taken when the light-scattering intensity had reached
a maximum value, corresponding to the maximum amount of aggregated peptides. Both
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sets of samples were then used to produce TEM micrographs. In the samples taken after
disassociation, it was difficult to find regions within the TEM grid that had aggregation and
all visible aggregates were made of clumps of residual, not entirely fibrillar morphologies
(Fig. 7b). The samples taken after re-aggregation contain fibrils indistinguishable from
those observed following the initial aggregation step (Fig. 7c).
V. DISCUSSION AND CONCLUSIONS
In this work we designed and experimentally tested a minimal peptide that, cross-linked
with an azobenzene group, self-associates into amyloid fibrils and dissociates from them
in a photo-controllable manner. The peptide is comprised of only 6 residues and has a
β-aggregation prone and a soluble conformation that are directed by the trans and cis
conformation of the cross-linker. To maximize the effects of the photo-isomerization, our
design was driven by the search for the most β-aggregation prone mutant in the trans state,
which at the same time has the highest possible solubility when in the cis state. Because of
the minimal length of the peptide, it was only necessary to systematically screen the three
central residues, flanked by the cross-linked cysteines. This allowed us to use equilibrium
aggregation simulations of peptide trimers in implicit solvent to determine the aggregation
properties of each of the possible sequences.
We then used the four most promising sequences to start implicit solvent aggregation
simulations of octamers, from which we chose the final sequence, Ac-Cys-His-Gly-Gln-Cys-
Lys-NH2. The stability of ordered octamers, spontaneously formed by this sequence, were
further validated in explicit solvent simulations. Finally, the cross-linked peptide was syn-
thesized and tested by performing aggregation experiments monitored by light-scattering,
fluorescence, and TEM. We conducted a reversible aggregation experiment where the sam-
ple was intermittently illuminated by UV-light, which switched the photo-linker into the
cis state inducing dissociation, and then allowed to associate when the illumination was
removed. Strikingly, the designed reversible photo-controlled fibrillation was confirmed by
the light-scattering measurements and TEM micrographs. Moreover, the fluorescence assays
corroborated the hypothesis of amyloid aggregation.
Molecular dynamics simulations of the octamer, both in implicit and explicit solvent,
provided insights into the structural properties and dynamics of the amyloid formation pro-
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cess. The ordered oligomers formed when the cross-linker is in the trans state, are organized
into a double four-stranded parallel β-sheet, and the sidechains are arranged to optimally
interact with the solvent. In detail, the hydrophobic azobenzene moieties are buried in-
side the oligomer and stabilize the interface of the two β-sheets, and the peptides’ polar
sidechains are pointing to the solvent. This “hydrophobic-in” and “polar-out” arrangement
of the sidechains is similar to those found in amyloid fibril models obtained from solid state
NMR data58–60. The assembly is stabilized by a variety of intermolecular interactions. In
addition to the peptide backbone hydrogen bonds typically present in amyloid aggregates,
we also observed ordered benzene stacking in the hydrophobic core, and hydrogen bonds
between the amide groups belonging to the cross-linkers. The oligomer explores different
arrangements of benzene packing, agreeing with observation that the amyloid assemblies
are dynamic and polymorphic8,61. It is worth noting that the cross-linker moiety, consist-
ing of amide and benzene groups, mimics the functional groups of Asn/Gln and Phe/Tyr
sidechains, which are known to promote and stabilize amyloid structures as revealed by
amyloid microcrystals62,63 and kinetic measurements64–66. The selection of polar His and
Gln residues at positions X2 and X4 derives from the maximization of the amphipathic
moment of the sequence, which was indirectly imposed by the bias of the filtering process
towards sequences that formed ordered and soluble structures at the same time. As men-
tioned above, glutamine and asparagine are common amino-acids in all amyloid sequences.
Less clear is the role of histidine, which was persistently highly ranked at position X2. The
pH dependence of aggregation detected in the experiment might be interpreted as an effect
of the protonation state of the histidine. Below pH 6 the peptides do not aggregate, due
to the electrostatic repulsion exerted by protonated histidine. Therefore, this amino acid
must have an important stabilization role in the aggregation. Interestingly, histidine appears
close to glutamine and asparagine in aggregation hotspots belonging to β-amyloid peptide
H13HQKLVFF20 and in the islet amyloid polypeptide H18SSNNFGAIL27. In both cases, pro-
tonated histidines or histidine mutations impair protofilament self-assembly for β-amyloid
peptide67 and noticeably slowed down aggregation kinetics of islet amyloid polypeptide68.
Ordered aggregation spontaneously nucleates in the simulations as a two-step process
within a disordered micellar oligomer. Initially a single β-sheet assembles, and successively
induces the formation of the second β-sheet. This scenario is consistent with the Nucleated
Conformational Conversion (NCC) mechanism69, where monomers initially assemble into
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amorphous oligomers, and then convert into ordered oligomers that are able to nucleate
the fibril formation. On-pathway disordered oligomers have been observed for a number of
polypeptide sequences, including Sup35 prion69, Aβ peptide70, and SH3 domain71, and have
been very well characterized by simplified peptide simulations34,72–74. Due to the amphi-
pathic nature of the cross-linked His.Gln peptide, oligomers formed in the cis state have a
micellar structure very similar to the early amorphous oligomers formed in the trans state.
We can speculate that during UV illumination the fibrils quickly dissociate into micelles
composed of cis monomers. When illumination is removed, nucleation occurs in the preex-
isting oligomers which act as seeds, explaining the more reproducible reaggregation kinetics
with respect to the initial aggregation, when the oligomers were not present. It is worth
noting that the aggregation kinetics of the simulations are apparently orders of magnitude
faster than the ones observed in the experiments. This is due to the much lower friction
coefficient of the implicit solvent with respect to real solvent, which is about 100 times more
viscous, and also due to the higher peptide concentration of the simulated system (5.3 mM)
with respect to the experimental sample (0.3 mM). Furthermore, as revealed by the TEM
micrographs of the disaggregated samples, the light scattering experiment is not sensitive
enough to detect small oligomers, which most likely form much earlier than amyloid fibrils.
The highly ordered octamer conformation suggests a possible structural model for the
fibrils observed in the TEM micrographs, where a single protofilament is obtained by repli-
cating the oligomer along its β-sheet axis. However, the thickness of the fibril observed in
TEM micrographs (about 60-80 A˚) is incompatible with the 15-25 A˚ inter β-sheet thickness
of the oligomer formed in silico. We can speculate that several identical protofilaments are
bundled together and stabilized by sidechain steric zipper interaction through the protofil-
ament hydrophilic surface, as observed in amyloid microcrystals62. It is also important to
note that individual oligomer strands of the order of 20 A˚ thick are difficult to detect with
TEM using the negative staining techniques used in these measurements.
The peptide designed presented here may have several applications. First, as described
in this work, the photoswitchable peptide can be used to control the amyloid aggregation
process. Second, the cross-linked peptide can be embedded in a larger sequence and can
act as a controllable amyloid hot-spot. Finally, by varying the intensity of UV illumination,
it is possible to change the equilibrium population ratio between cis and trans states and
effectively control the population difference between the β-aggregation prone and the solu-
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ble conformations of the peptides in the sample, modulating the pathways of the amyloid
aggregation, as previously illustrated by a coarse grained model of an amphipathic amyloid
peptide75.
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Design stage Sequences Number of sequence Approach Solvent model System size Linker state
selection CA[A,G]AC 2 simulation SASA trimer T
selection CXGXC 169 simulation SASA trimer T
selection CXGXCK 26 simulation FACTS trimer T,C
selection selected sequences 4 simulation FACTS octamer T,C
validation selected sequences 1 simulation TIP3P octamer T
validation selected sequences 1 experiments multimer T,C
TABLE 1: Design procedures. The design pipeline was organized as a progressive selection of
sequences based on the results of molecular dynamics simulation with increasingly accurate solvent
models: Solvent Accessible Surface Area implicit solvent (SASA)47, Fast Analytical Continuum
Treatment of Solvation (FACTS)48 and explicit TIP3P water molecules76.
Sequence Time(ns) rP2 Rg InterHB
CAGAC 420 0.62 7.89 1.75
CAAAC 420 0.06 9.09 0.40
TABLE 2: Effect of glycine and alanine at position X3. Nematic order parameter ratio
(rP2), radius of gyration (Rg), and intermolecular backbone hydrogen bonds (InterHB) calculated
on trimer aggregation trajectory of two variants that have either alanine or glycine at position X3.
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X2.X4 Cis Trans Score
His.Ala 6 4 10
His.Gln 7 8 15
Phe.Ala 11 6 17
His.Met 9 11 20
His.Leu 12 9 21
Tyr.Tyr 19 2 21
His.Phe 16 7 23
His.Asn 8 16 24
His.His 14 10 24
Phe.Tyr 21 3 24
Met.Ala 4 21 25
His.Trp 26 1 27
Met.Trp 10 17 27
Ser.Ala 1 26 27
Thr.Met 3 24 27
Val.Thr 2 25 27
Val.Asn 5 23 28
Leu.Phe 18 12 30
Phe.Trp 25 5 30
Phe.His 17 15 32
Phe.Met 15 18 33
Leu.His 13 22 35
Tyr.Phe 22 14 36
Phe.Phe 24 13 37
Trp.Met 20 19 39
Trp.Val 23 20 43
TABLE 3: Final ranks. Final ranks of the peptide sequences taken from the second round of
aggregation simulations. The score is calculated as the sum of the rank numbers obtained from the
cis and trans simulations (Tabs. S2 and S3). A low score (i.e., high rank) corresponds to sequences
that are highly prone to form β interaction in the trans state and at the same time display high
solubility in the cis state. The highest ranking sequences are highlighted in boldface in the table,
and are chosen to start octameric aggregation simulations. The full sequence of the simulated
cross-linked peptide is Ac-Cys-X2-Gly-X4-Cys-Lys-NH2.
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Ac - X1 X2 X3 X4 X5 X6 - NH2
K
G or A
A, F, H, I, L, M, 
N, Q, S, T, V, Y, W
A, F, H, I, L, M, 
N, Q, S, T, V, Y, W
C C
cross-linker
FIG. 1: Photoswitchable aggregation. Top: Diagram showing the basic structure of the
minimal peptide sequence design for photo-switchable aggregation and a summary of all explored
variants. Bottom: The cross-linked peptide undergoes isomerization between the cis and the
trans conformation upon UV illumination (left) and UV-light absence (right). The backbone of
monomer in the cis conformation is collapsed and unable to form cross-β interactions. In the trans
conformation, the backbone is extended and prone to form amyloid-like interactions.
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FIG. 2: Simulation snapshots. (a-d) Octamer conformations extracted from implicit solvent
simulation trajectories of aggregation with the cross-linker in the trans conformation. For clarity
the sidechains that connect the azobenzene to the peptide backbone are not represented. The
snapshots correspond to the conformations with the highest amount of backbone hydrogen bonds,
explored by the full single peptide sequence library. (e) Aggregation trajectory snapshot when the
cross-linker is in the cis conformation, showing a micellar-like morphology. (f) From left to right:
time average of the number of intermolecular backbone hydrogen bonds, polar order parameter
P1, nematic order parameter P2 for aggregation simulations in the trans state, average radius of
gyration Rg for the simulations in the cis state. Error bars indicate the standard deviation. The
averages are calculated omitting the first 100 ns of simulation.
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FIG. 3: Octamer trajectory analysis. Number of intramolecular (black line) and intermolecular
(red line) hydrogen bonds for the octamer simulations of the His.Gln peptide when the cross-linker
is in trans configuration (a) and cis (b) configuration. The snapshots depict the aggregation
process at selected times when the cross-linker is in the trans state. (c) comparison between radius
of gyration frequency histograms of the trans and cis simulations.
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FIG. 4: Structure of the amyloid oligomer. Structural analysis of the explicit solvent sim-
ulation trajectories of the ordered oligomer. The His.Gln peptide with the cross-linker in the
trans conformation. (a) Top: Cα-RMSD timeseries with respect to the starting structure for three
simulations. In one of the simulations two peptides disaggregate from the oligomer, resulting in
an increase of the octamer RMSD (red line), whereas the remaining six peptides are structurally
stable as indicated by the RMSD calculated on the aggregated peptides (orange line). Bottom:
backbone and cross-linker amide intermolecular hydrogen-bonds calculated for simulation 1. The
azobenzenes are arranged in two possible configurations (b,c) and packed inside the oligomer to
form aromatic stacking interactions (d). The oligomer is stabilized by intra β-sheet (e) and inter
β-sheet hydrogen-bonds between the cross-linkers (f), represented by the red dashed lines in the
figures.
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FIG. 5: Light scattering. Light scattering was measured over 165 hours continuously for a
newly suspended solution of His.Gln peptide. (a) A full scattering trajectory showing the initial
lag-phase, aggregation and stable scattering maximum by 15 hours and then four sequential photo-
controlled disassociation and aggregation events. Downward arrows point to when UV illumination
was initiated and upward arrows point to when illumination was stopped. (b) Overlay of the four
normalized disassociation events. Each colored curve is taken from the trajectory shown in (a)
and aligned such that each corresponding colored downward arrow is set to t = 0 minutes. (c)
Overlay of the four normalized aggregation events. where t = 0 minutes corresponds to when UV
illumination is removed and shown in (a) by corresponding colored downward arrows.
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FIG. 6: PTAA fluorescence. Fluorescence spectra of PTAA in solution with the His.Gln peptide
before UV illumination (black), when light scattering measurements are high, and after UV (red)
illumination, when scattering measurements have reached the minimum intensity. Top: Emission
spectra (excitation at 400 nm). Bottom: Excitation spectra (emission at 600 nm).
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FIG. 7: Transmission electron microscopy. (a) TEM image of amyloid-like fibrils formed by
the His.Gln peptide at pH 7 with the photo-linker in the trans conformation. (b) The same peptide
at pH 7 after constant UV illumination forcing the photo-linker into the cis conformation and fibrils
to disassociate. The cis fibrils look shorter and more fragile than their trans counterparts. (c) The
same peptide after illumination has been removed and the photo-linker has returned to the trans
state, allowing reaggregation of the peptide.
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